Differential gene expression in tumorigenic and nontumorigenic HeLa x normal human fibroblast hybrid cells

Molecular Carcinogenesis

Volumn 26, Issue 4, 1999, Pages 298-304

  Tsujimoto, Hiroyuki ^a,b   Nishizuka, Satoshi ^a   Redpath, J Leslie ^a   Stanbridge, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Differential display; HeLa cell; Hybrid cell; Intestinal alkaline phosphatase; Tumorigenicity

Indexed keywords

ALKALINE PHOSPHATASE; GLYCOPROTEIN; GROWTH FACTOR; KERATIN; MEMBRANE RECEPTOR; PHOSPHATASE; PHOSPHOTRANSFERASE; REGULATOR PROTEIN;

ARTICLE; CARCINOGENESIS; CELL FUSION; CELL HYBRIDIZATION; CHROMOSOME 11; CONTROLLED STUDY; FIBROBLAST; GENE; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; HELA CELL; HUMAN; HUMAN CELL; HYBRID CELL; MOLECULAR CLONING; PRIORITY JOURNAL;

EID: 0032733652     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M     Document Type: Article

References (41)

1. Stanbridge EJ. Suppression of malignancy in human cells. Nature 1976;260:17-20.
2. Stanbridge EJ, Der CJ, Doerson CJ, et al. Human cell hybrids: Analysis of transformation and tumorigenicity. Science 1982;215:252-259.
3. Klinger HP. Suppression of tumorigenicity. Cytogenet Cell Genet 1982;32:68-84.
4. Der CJ, Stanbridge EJ. A tumor-specific membrane phosphoprotein in human cell hybrids. Cell 1981;26:429-438.
5. Latham KL, Stanbridge EJ. Identification of the Hela tumor-associated antigen, p75/150, as intestinal alkaline phosphatase and evidence for its transcriptional regulation. Proc Natl Acad Sci USA 1990;87:1263-1267.
6. Stanbridge EJ, Flandemeyer RR, Daniels DW, Nelson-Rees WA. Specific chromosome loss associated with expression of tumorigenicity in human cell hybrids. Somatic Cell Genet 1981;7:699-712.
7. Srivatsan ES, Benedict WF, Stanbridge EJ. Implication of chromosome 11 in the suppression of neoplastic expression in human cell hybrids. Cancer Res 1986;46:6174-6179.
8. Kaelbling M, Klinger HP. Suppression of tumorigenicity in somatic cells. III. Cosegregation of human chromosome 11 of a normal cell and suppression of tumorigenicity in intra-species hybrids of normal diploid × malignant cells. Cytogenet Cell Genet 1986;41:67-70.
9. Saxon PJ, Srivatsan EJ, Stanbridge EJ. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of Hela cells. EMBO J 1986;5:3461-3466.
10. Mendonca MS, Antoniono RJ, Latham KM, Stanbridge EJ, Redpath JL. Characterization of intestinal alkaline phosphatase expression and the tumorigenic potential of gamma-irradiated HeLa × fibroblast cell hybrids. Cancer Res 1991; 51:4455-4462.
11. Latham KM, Stanbridge EJ. Examination of the oncogenic potential of a tumor associated antigen, intestinal alkaline phosphatase, in HeLa × fibroblast cell hybrids. Cancer Res 1992;52:616-622.
12. Stanbridge EJ, Wilkinson J. Dissociation of anchorage independence from tumorigenicity in human cell hybrids. Int J Cancer 1980;26:1-8.
13. Mendonca MS, Fasching CL, Srivatsan ES, Stanbridge EJ, Redpath JL. Loss of a putative tumor suppressor locus after gamma-ray induced neoplastic transformation of HeLa × skin fibroblast human cell hybrids. Radiat Res 1995;143: 34-44.
14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
15. Diachenko LB, Ledesma J, Chenchik AA, Siebert PD. Combining the technique of RNA fingerprinting and differential display to obtain differentially expressed mRNAs. Biochem Biophys Res Commun 1996;219:824-828.
16. Sambroke J, Fritsch FF, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989. 10.13 p.
17. http://www.ncbi.nlm.nih.gov/Ømin
18. Liang P, Bauer D, Averboukh L, et al. Analysis of altered gene expression by differential display. Methods Enzymol 1994;254:1227-1234.
19. Travers H, French NS, Norton JD. Suppresion of tumorigenicity in Ras-transformed fibroblasts by alpha 2(I) collagen. Cell Growth Differ 1996;7:1353-1360.
20. Skonier J, Bennett K, Rothwell V, et al. Big-h3: A transforming growth factor-β-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol 1994;13:571-584.
21. Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation of heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neurodermal origin. Cancer Res 1993;53:3327-3335.
22. Brannan CI, Dees EC, Ingram RS, Tilghman SM. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990;10:28-36.
23. Hao Y, Crenshow T, Moulton T, Newcomb E, Tycko B. Tumor-suppressor activity of H19 RNA. Nature 1993;365: 764-767.
24. Zhang Y, Tycko B. Monoallelic expression of the human H19 gene. Nat Genet 1992;1:40-44.
25. Cates CA, Michael RL, Stayrook KR, et al. Prenylation of oncogenic human PTPCAAX protein tyrosine phosphatases. Cancer Lett 1996;110:49-55.
26. Caulin C, Bauluz C, Gandarillas A, Cno A, Quintanilla M. Changes in keratin expression during malignant progression of transformed mouse epidermal keratinocyte. Exp Cell Res 1993;204:11-21.
27. Troyanovsky SM, Leube RE, Franke WW. Characterization of the human gene encoding cytokeratin 17 and its expression pattern. Eur J Cell Biol 1992;59:127-137.
28. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-971.
29. DeWet W, Bernard M, Benson-Chanda V, et al. Organization of the human pro-alpha 2(I) collagen gene. J Biol Chem 1987;262:16032-16036.
30. Skonier J, Neubauer M, Madeisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of Big-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-β. DNA Cell Biol 1992;11:511-522.
31. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994;91: 5657-5661.
32. Oh Y. IGFBPs and neoplastic models: New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine 1997;7:111-113.
33. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor binding protein-3 action. J Biol Chem 1995;270: 13589-13592.
34. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-649.
35. Cates CA, Michael RL, Stayrook KR, et al. Prenylation of oncogenic human PTPCAAX protein tyrosine phosphatases. Cancer Lett 1996;110:49-55.
36. Zemel S, Bartolomei M, Tilghman S. Physiological linkage of two mammalian imprinted genes, H19 and insulin-like growth factor 2. Nat Genet 1992;2:61-65.
37. Looijenga LHJ, Verkerk AJMH, Groot N, Hochberg AA, Oosterhuis J. W. H19 in normal development and neoplasia. Mol Reprod Dev 1997;46:419-439.
38. Albers K, Fuchs E. The molecular biology of intermediate filament proteins. Int Rev Cytol 1992;143:243-279.
39. Harris H, Rawlins J, Sharps J. A different approach to tumor suppression. The Alexandra Kefaileds Memorial Lecture. J Cell Sci 1996;109:2189-2197.
40. Fuchs E, Green H. Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell 1980;19:1033-1042.
41. Cheng C, Kilkenny AE, Roop D, Yuspa SH. The v-ras oncogene inhibits the expression of differentiation markers and facilitates expression of cytokeratins 8 and 18 in mouse keratinocytes. Mol Carcinog 1990;3:363-373.